HC Wainwright reiterated their buy rating on shares of Genelux (NASDAQ:GNLX - Free Report) in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock. HC Wainwright also issued estimates for Genelux's Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.84) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $1.23 EPS and FY2029 earnings at $2.58 EPS.
Genelux Price Performance
NASDAQ GNLX traded up $0.05 on Tuesday, reaching $3.08. The company had a trading volume of 203,076 shares, compared to its average volume of 205,897. The firm has a market cap of $106.38 million, a price-to-earnings ratio of -3.24 and a beta of -1.41. Genelux has a fifty-two week low of $1.60 and a fifty-two week high of $6.50. The business has a 50 day moving average of $4.06 and a two-hundred day moving average of $3.10.
Genelux (NASDAQ:GNLX - Get Free Report) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). As a group, research analysts predict that Genelux will post -0.88 earnings per share for the current fiscal year.
Institutional Trading of Genelux
A number of institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company's stock valued at $749,000 after purchasing an additional 89,854 shares during the period. Marshall Wace LLP increased its holdings in Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock worth $368,000 after purchasing an additional 52,958 shares in the last quarter. LPL Financial LLC boosted its holdings in shares of Genelux by 72.3% during the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company's stock worth $222,000 after buying an additional 39,516 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Genelux during the 3rd quarter worth approximately $59,000. Finally, D.A. Davidson & CO. bought a new stake in shares of Genelux in the 4th quarter valued at $51,000. Institutional investors own 37.33% of the company's stock.
Genelux Company Profile
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Read More
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
